Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Number of holders
-
108
-
Total 13F shares, excl. options
-
38,816,393
-
Shares change
-
-6,739,812
-
Total reported value, excl. options
-
$107,856,591
-
Value change
-
-$8,601,646
-
Put/Call ratio
-
88%
-
Number of buys
-
64
-
Number of sells
-
-63
-
Price
-
$2.78
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q2 2023
165 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 108 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38,816,393 shares
of 1,079,784,035 outstanding shares and own 3.6% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (10,333,301 shares), BlackRock Inc. (9,498,666 shares), STATE STREET CORP (2,777,236 shares), GEODE CAPITAL MANAGEMENT, LLC (2,730,452 shares), JPMORGAN CHASE & CO (1,478,953 shares), NORTHERN TRUST CORP (1,161,699 shares), CREDIT SUISSE AG/ (1,016,494 shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (978,547 shares), NATIONAL BANK OF CANADA /FI/ (795,400 shares), and ALLEN HOLDING INC /NY (687,571 shares).
This table shows the top 108 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.